虎踞乙肝胶囊联合阿德福韦酯抗慢性乙肝肝纤维化的临床研究  

Clinical Study on Anti- liver Fibrosis by Hujuyigan Capsule Combined with Adevofovir

作　　者：蒋淑莲[1] 吴民祥[1] 文剑[1] 

机构地区：[1]南京市第二医院,江苏南京210003

出　　处：《辽宁中医杂志》2015年第5期1031-1033,共3页Liaoning Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金资助项目(81000997)

摘　　要：目的:观察虎踞乙肝胶囊联合阿德福韦酯(ADV)治疗慢性乙肝肝纤维化的疗效。方法:采用随机对照方法,将59例慢性乙肝患者随机分为治疗组和对照组,对照组35例单独应用口服阿德福韦酯治疗,治疗组24例则在对照组治疗基础上加用口服虎踞乙肝胶囊。治疗6个月,治疗前后检测ALT、HBV-DNA、e抗原以及Piii P、HA、TGF-β1并进行统计学分析。结果:治疗组ALT复常率、HBV-DNA以及e抗原转阴率均优于对照组,但无统计学性差异(P>0.05);两组肝纤维化指标Piii P、HA及肝纤维化刺激因子TGF-β1均显著降低,且治疗组降低程度明显优于对照组,有统计学差异(P<0.05)。结论:虎驹乙肝胶囊联合ADV治疗慢性乙型肝炎在降低肝纤维化指标、抑制HSC刺激因子TGF-β1方面较单用ADV具有更好的疗效,值得进一步临床推广。Objective ： To observe the curative effect of Hujuyigan capsule and adevofovir on anti - liver fibrosis in HBV chronic infection patients. Methods：59 patients with HBV chronic infection were randomly divided into two groups. 35 cases in control group were treated with adevofovir alone. 24 cases in treatment group were given Hujuyigan capsule on the basis of control group.Both groups were treated for 6 months. Before and after treatment, ALT, HBV - DNA, eAg and PiiiP, HA, TGF - β1 were detected and analyzed. Results ：The restoration rates of ALT, HBV -DNA and HBeAg in treatment group were better than those in control group, but there were no significant difference between the two groups. The rates of liver fibrosis indicators were significantXy re- duced in both groups,and the effect was significantly better in treatment group than in control group（P 〈0.05）. Conclusion：Hu- juyigan capsule combined with adevofovir may be a better therapy for anti - liver fibrosis in HBV chronic infection patients.

关 键 词：虎踞乙肝胶囊 阿德福韦酯 肝纤维化 

分 类 号：R512.62[医药卫生—内科学]